Literature DB >> 8168414

Blood transfusion and survival in colorectal cancer.

D M Sibbering1, A P Locker, J D Hardcastle, N C Armitage.   

Abstract

PURPOSE: This study examined the effect of blood transfusion on the prognosis of patients undergoing surgery for colorectal cancer.
METHODS: Potentially curative resections for colorectal cancer were performed in 266 patients who were followed prospectively, with a minimum follow-up of 41 months. They were divided into transfused (n = 121) and nontransfused (n = 145) groups according to their perioperative blood transfusion requirements.
RESULTS: There were significantly more rectal tumors (chi 2 = 9.5, df = 1, P = 0.002) and fixed tumors (chi 2 = 4.5, df = 1, P = 0.03) in the transfused group. There was no statistically significant difference between the two groups with regard to recurrence-free survival (chi 2 = 1.1, df = 1, P = 0.3) and overall survival (chi 2 = 2.8, df = 1, P = 0.09).
CONCLUSION: In this study we have found no statistically significant effect of perioperative blood transfusion on the prognosis of colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168414     DOI: 10.1007/bf02053597

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

1.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

Review 2.  Perioperative blood transfusions for the recurrence of colorectal cancer.

Authors:  A Amato; M Pescatori
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Perioperative blood transfusion is associated with post-operative infectious complications in patients with Crohn's disease.

Authors:  Nan Lan; Luca Stocchi; Yi Li; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.